drugset / Trial / NCT01823510

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510 ↗

Phase 4 Completed 20 enrolled Juan J Badimon AstraZeneca · collab
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.

Timeline

Start
2013-07
Primary completion
2016-05-10
Completion
2016-05-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg —
Subject Ticagrelor Small molecule 90 mg —
Background Aspirin Small molecule 81 mg —